Automatic implantable cardioverter defibrillator (AICD) implantation as secondary prevention of cardiac sarcoidosis-associated ventricular tachycardia
  • Fares Saliba
    Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA
  • Jonathan Mina
    Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA
  • Laurence Aoun
    Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA
  • Georges Khattar
    Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA
  • Elie Bou Sanayeh
    Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA
  • Omar Mourad
    Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA
  • Saif Abu Baker
    Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA

Keywords

Sarcoidosis, arrhythmia, ventricular tachycardia

Abstract

 

Background: Cardiac sarcoidosis can cause a wide range of symptoms, including shortness of breath, chest pain, oedema, and fatal arrhythmias such as ventricular tachycardia (VT). Because the symptoms can be nonspecific, diagnosing cardiac sarcoidosis can be challenging. Treatment options may include corticosteroids to reduce inflammation, immunosuppressive drugs to prevent further damage, medications to control symptoms, ablation procedures, and defibrillators to prevent cardiac arrest.
Case: A 60-year-old woman who has sarcoidosis affecting multiple organs including cardiac sarcoidosis, non-ischemic cardiomyopathy with reduced ejection fraction, and hypertension, was admitted with tachycardia, shortness of breath, and a recently fired automatic implantable cardioverter defibrillator (AICD). Three months prior, the patient was admitted for a syncopal episode and diagnosed with cardiac sarcoidosis through cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET), which demonstrated active inflammation, and an AICD was implanted. During this admission, the patient had an episode of ventricular tachycardia and was treated with amiodarone and lidocaine. The patient received steroids, sacubitril/valsartan, and methotrexate. After 48 hours of observation, the patient was discharged without further events.
Conclusion: Cardiac sarcoidosis is a rare but serious disease that can lead to life-threatening cardiac complications such as ventricular tachycardia. Early diagnosis and aggressive management are crucial for improving outcomes and preventing sudden cardiac death. AICD implantation as a secondary prevention in cardiac sarcoidosis might prevent cardiac arrest.

VIEW THE ENTIRE ARTICLE

References

  • Arkema EV, Cozier YC. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med 2020;26:527–534.
  • Nery PB, McArdle BA, Redpath CJ, Leung E, Lemery R, Dekemp R, et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol 2014;37:364–374.
  • Salama A, Abdullah A, Wahab A, Eigbire G, Hoefen R, Alweis R. Cardiac sarcoidosis and ventricular arrhythmias. A rare association of a rare disease. A retrospective cohort study from the National Inpatient Sample and current evidence for management. Cardiol J 2020;27:272–277.
  • Yasir M, Masood I, Aiman A, Afaq S, Bakaya A. Cardiac sarcoidosis presenting as recurrent ventricular tachycardia: a case report. Cases J 2009;2:9353.
  • Markatis E, Afthinos A, Antonakis E, Papanikolaou IC. Cardiac sarcoidosis: diagnosis and management. Rev Cardiovasc Med 2020;21:321–338.
  • Birnie DH, Kandolin R, Nery PB, Kupari M. Cardiac manifestations of sarcoidosis: diagnosis and management. Eur Heart J 2017;38:2663–2670.
  • Régis C, Benali K, Rouzet, F. FDG PET/CT imaging of sarcoidosis. Semin Nucl Med 2023;53:258–272.
  • Ipek E, Demirelli S, Ermis E, Inci S. Sarcoidosis and the heart: a review of the literature. Intractable Rare Dis Res 2015;4:170–80.
  • Bakker ALM, Mathijssen H, Azzahhafi J, Swaans MJ, Veltkamp M, Keijsers RGM, et al. Effectiveness and safety of infliximab in cardiac sarcoidosis. Int J Cardiol 2021;330:179–185.
  • Azoulay LD, Waintraub X, Haroche J, Amoura Z, Cohen Aubart F. Factors associated with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis: a meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:17–23.
  • Kazmirczak F, Chen KA, Adabag S, von Wald L, Roukoz H, Benditt DG, et al. Assessment of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis. Circ Arrhythm Electrophysiol 2019;12:e007488.
  • Views: 159
    HTML downloads: 16
    PDF downloads: 120


    Published: 2024-05-02
    Issue: 2024: Vol 11 No 6 (view)


    How to cite:
    1.
    Saliba F, Mina J, Aoun L, Khattar G, Bou Sanayeh E, Mourad O, Abu Baker S. Automatic implantable cardioverter defibrillator (AICD) implantation as secondary prevention of cardiac sarcoidosis-associated ventricular tachycardia. EJCRIM 2024;11 doi:10.12890/2024_004469.

    Most read articles by the same author(s)